Please ensure Javascript is enabled for purposes of website accessibility Andy Acker, CFA - Janus Henderson Investors
For financial professionals in the UK

Andy Acker, CFA

Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager on the Health Care and Biotech Teams at Janus Henderson Investors. He is also the Health Care Sector Lead. Andy was an assistant portfolio manager from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 28 years of financial industry experience.

Download hi-res headshot

Articles Written

Hangover cure: Tapping into global growth with thematic equities
Timely & Topical

Hangover cure: Tapping into global growth with thematic equities

Janus Henderson’s recent Global Investment Summit explored growth drivers in equities, noting record levels of innovation in healthcare and technology as well as developments in real estate and sustainability.

Identifying AI opportunities in healthcare
Timely & Topical

Identifying AI opportunities in healthcare

Artificial intelligence is only beginning to make inroads into the healthcare sector. Here’s how investors might benefit today.

Why healthcare stocks could catch a break this election year
Timely & Topical

Why healthcare stocks could catch a break this election year

The sector has historically underperformed in the lead-up to U.S. presidential elections, but that may not be the case in 2024.

Global Life Sciences – strategy update

Global Life Sciences – strategy update

Please watch an update on Global Life Sciences strategy from Andy Acker, Portfolio Manager on the Health Care and Biotech Teams, which took place on 22 February 2024.

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world
Features & Outlooks

Global Perspectives: Investing in the small- and midsize healthcare companies innovating for a graying world

How healthcare’s small- and mid-cap companies could benefit from one of today’s key macroeconomic growth drivers: aging populations.

Healthcare’s small- and mid-cap opportunities amid aging populations
Features & Outlooks

Healthcare’s small- and mid-cap opportunities amid aging populations

With populations in some of the largest economies quickly graying, innovative small- and mid-cap healthcare companies could deliver new growth opportunities for investors.

Biotech stocks gain momentum from lower rates, innovation, and M&A
Timely & Topical

Biotech stocks gain momentum from lower rates, innovation, and M&A

Several factors are coming together that could help push the biotech sector higher.

Research in Action: Healthcare’s setup for 2024 strengthens
Features & Outlooks

Research in Action: Healthcare’s setup for 2024 strengthens

With depressed valuations and accelerating innovation, we believe the sector offers an attractive combination for long-term investors.

Healthcare stocks: Positioned for a smoother ride in 2024?
Timely & Topical

Healthcare stocks: Positioned for a smoother ride in 2024?

Andy Acker and Dan Lyons share their outlook, saying a rapid pace of innovation and attractive valuations could propel the sector higher.

Medical devices, tools, and insurers make the case for a rebound
Timely & Topical

Medical devices, tools, and insurers make the case for a rebound

These healthcare subsectors offer an attractive combination of long-term growth drivers at below-average valuations.

Global Life Sciences – Q3 strategy update
Features & Outlooks

Global Life Sciences – Q3 strategy update

Andy Acker, Portfolio Manager on the Health Care Team gives a quarterly update on the Global Life Sciences strategy, as well as shares his latest market perspectives and outlook.

Four questions: Why invest in healthcare now?
Timely & Topical

Four questions: Why invest in healthcare now?

Hear how advances in drug development, patient outcomes, and other trends are impacting the investment outlook for healthcare.